Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.
Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis and more recently was given emergency use authorization as therapy in combination with remdesivir for severe COVID-19. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators. Rheumatoid arthritis is a progressive autoimmune disease commonly associated with discomfort, diasability, and joint damage. Throughout disease progression, the disease may further lead to joint erosions and deformities, causing premature mortality, functional impairment, and reduced quality of life. While there are several disease modifying antirheumatic drugs (DMARDs) available for treatment, patients often experience inadequate threapeutic resposes to these drugs. In animal models of inflammatory arthritis, baricitinib was shown to have significant anti-inflammatory effects, but also led to preservation of cartilage and bone, with no detectable suppression of humoral immunity or adverse hematologic effects. In the EU, baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate. It is marketed under the trade name Olumiant. Baricitinib in combination with [remdesivir] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on 19 November 2020. Baricitinib; 1187594-09-7; INCB028050; LY3009104; 2-(3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-1-(Ethylsulfonyl)Azetidin-3-Yl)Acetonitrile; INCB 028050; Â Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com
LED lighting market will increase 30 industrial chain next year
According to reports, Taiwan's supply chain companies expect global LED lighting market output to increase by 30 in 2015, and doubling shipments will offset the negative impact of falling prices by 30-35. According to research institute LEDinside, the total output of global LED lighting will reach 25.7 billion US dollars in 2015, accounting for 31.3% of the total output of the overall lighting market. The industry expects that European production capacity will account for 23% of the global LED lighting market next year. 21, the United States accounted for 19. Industry sources said that compared to the overall growth of the LED lighting market, the LED backlight market will decline, mainly because the new LED TV requires less chips than the backlight LCD TV, while the price of the backlight LED chip It is also falling. An important trend in the LED industry recently is the continued growth in demand for indoor LED lighting equipment and the decline in LED chip/component business. According to the financial report released by CREE, the leading LED lighting company in the United States, the sales of LED lighting products of the company increased by 51 to 223 million US dollars in the third quarter of this year, while the sales of chip/component business decreased by 20 to 173.6 million. According to US semiconductor supplier Rubicon Technology (RBCN), the weak LED backlight market will have a significant impact on the company's current quarterly results, and it is expected that demand will not pick up until the first quarter of next year. According to the analysis, with the widespread application of LED lighting products worldwide, LED lighting enterprises will grow at a high speed, and the scale effect will gradually be reflected. At the same time, the price of LED lighting products is lower, which further accelerates the reshuffle of the LED lighting market. The continuous improvement of the degree will bring long-term benefits to enterprises with technical strength and scale advantages.